Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$302.4 million.

  • 4D Molecular Therapeutics' Cash from Investing Activities fell 34.88% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year increase of 113.58%. This contributed to the annual value of -$302.4 million for FY2024, which is 361.36% down from last year.
  • As of FY2024, 4D Molecular Therapeutics' Cash from Investing Activities stood at -$302.4 million, which was down 361.36% from $115.7 million recorded in FY2023.
  • 4D Molecular Therapeutics' Cash from Investing Activities' 5-year high stood at $115.7 million during FY2023, with a 5-year trough of -$302.4 million in FY2024.
  • In the last 3 years, 4D Molecular Therapeutics' Cash from Investing Activities had a median value of -$17.1 million in 2022 and averaged -$67.9 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Cash from Investing Activities crashed by 17,168.00% in 2021, and later skyrocketed by 778.69% in 2023.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Cash from Investing Activities stood at -$1.0 million in 2020, then tumbled by 17,168.00% to -$172.7 million in 2021, then spiked by 90.13% to -$17.1 million in 2022, then skyrocketed by 778.69% to $115.7 million in 2023, then slumped by 361.36% to -$302.4 million in 2024.